Lupin receives FDA approval for Levothyroxine Sodium Tablets USP

Deepthi | Myequity news | Date : 21-01-2019 15:30:00 IST

Pharma major Lupin has received approval for its Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie, Inc’s Synthroid Tablets.

It is indicated for Hypothyroidism and Pituitary Thyrotropin. Levothyroxine Sodium Tablets had annual sales of approximately USD 2519.6 million in the US (IQVIA MAT September 2018).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

More from Myequity